Olomoucine
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H406180

CAS#: 101622-51-9

Description: Olomoucine is a CDK inhibitor that competes for the ATP binding site of the kinase. Olomoucine was shown to reversibly arrest differentiated Petunia cells induced to divide at G1 phase and cycling Arabidopsis cells in late G1 and G2.

Chemical Structure

img
Olomoucine
CAS# 101622-51-9
Instruction

Theoretical Analysis

Hodoodo Cat#: H406180
Name: Olomoucine
CAS#: 101622-51-9
Chemical Formula: C15H18N6O
Exact Mass: 298.15
Molecular Weight: 298.350
Elemental Analysis: C, 60.39; H, 6.08; N, 28.17; O, 5.36

Price and Availability

Size Price Availability Quantity
5mg USD 285 2 Weeks
10mg USD 520 2 Weeks
25mg USD 950 2 Weeks
Bulk inquiry

Synonym: Olomoucine

IUPAC/Chemical Name: 6-(Benzylamino)-2-(2-hydroxyethylamino)-9-methylpurine

InChi Key: GTVPOLSIJWJJNY-UHFFFAOYSA-N

InChi Code: InChI=1S/C15H18N6O/c1-21-10-18-12-13(17-9-11-5-3-2-4-6-11)19-15(16-7-8-22)20-14(12)21/h2-6,10,22H,7-9H2,1H3,(H2,16,17,19,20)

SMILES Code: CN1C=NC2=C(NCC3=CC=CC=C3)N=C(NCCO)N=C12

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >5 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:         

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 298.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Hofman J, Ahmadimoghaddam D, Hahnova L, Pavek P, Ceckova M, Staud F. Olomoucine II and purvalanol A inhibit ABCG2 transporter in vitro and in situ and synergistically potentiate cytostatic effect of mitoxantrone. Pharmacol Res. 2012 Mar;65(3):312-9. doi: 10.1016/j.phrs.2011.11.017. Epub 2011 Dec 6. PubMed PMID: 22173067.

2: Korinkova G, Cwiertka K, Paprskarova M, Dzubak P, Hajduch M. The radiosensitising effect of olomoucine derived synthetic cyclin-dependent kinase inhibitors. Neoplasma. 2010;57(2):161-9. PubMed PMID: 20099981.

3: Holcakova J, Tomasec P, Bugert JJ, Wang EC, Wilkinson GW, Hrstka R, Krystof V, Strnad M, Vojtesek B. The inhibitor of cyclin-dependent kinases, olomoucine II, exhibits potent antiviral properties. Antivir Chem Chemother. 2010 Jan 5;20(3):133-42. doi: 10.3851/IMP1460. PubMed PMID: 20054100; PubMed Central PMCID: PMC2948526.

4: Małecki JM, Bentke A, Ostrowska B, Laidler P. Cytochalasin D, LY294002 and olomoucine synergize in promoting death of melanoma cells through activation of caspase-3 and apoptosis. Melanoma Res. 2010 Feb;20(1):52-8. doi: 10.1097/CMR.0b013e328332f1e6. PubMed PMID: 20010439.

5: Wandl S, Wesierska-Gadek J. Is olomoucine, a weak CDK2 inhibitor, able to induce apoptosis in cancer cells? Ann N Y Acad Sci. 2009 Aug;1171:242-9. doi: 10.1111/j.1749-6632.2009.04700.x. PubMed PMID: 19723061.

6: Fei XF, Qin ZH, Xiang B, Li LY, Han F, Fukunaga K, Liang ZQ. Olomoucine inhibits cathepsin L nuclear translocation, activates autophagy and attenuates toxicity of 6-hydroxydopamine. Brain Res. 2009 Apr 6;1264:85-97. doi: 10.1016/j.brainres.2009.01.057. Epub 2009 Feb 6. PubMed PMID: 19368812.

7: Siller M, Anzenbacher P, Anzenbacherova E, Dolezal K, Popa I, Strnad M. Interactions of olomoucine II with human liver microsomal cytochromes P450. Drug Metab Dispos. 2009 Jun;37(6):1198-202. doi: 10.1124/dmd.108.025502. Epub 2009 Feb 27. PubMed PMID: 19251823.

8: Jhou RS, Sun KH, Sun GH, Wang HH, Chang CI, Huang HC, Lu SY, Tang SJ. Inhibition of cyclin-dependent kinases by olomoucine and roscovitine reduces lipopolysaccharide-induced inflammatory responses via down-regulation of nuclear factor kappaB. Cell Prolif. 2009 Apr;42(2):141-9. doi: 10.1111/j.1365-2184.2009.00584.x. Epub 2009 Feb 24. PubMed PMID: 19250292.

9: Tripathi BK, Stepp MA, Gao CY, Zelenka PS. The Cdk5 inhibitor olomoucine promotes corneal debridement wound closure in vivo. Mol Vis. 2008 Mar 17;14:542-9. PubMed PMID: 18385789; PubMed Central PMCID: PMC2274924.

10: Wesierska-Gadek J, Gueorguieva M, Kramer MP, Ranftler C, Sarg B, Lindner H. A new, unexpected action of olomoucine, a CDK inhibitor, on normal human cells: up-regulation of CLIMP-63, a cytoskeleton-linking membrane protein. J Cell Biochem. 2007 Dec 15;102(6):1405-19. PubMed PMID: 17975794.